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Abstract.
BACKGROUND: Oncotype DX R© test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+)
breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied.
OBJECTIVE: We hypothesize a positive association between the Oncotype DX R© recurrence score (RS) and the percentage
tumor response (%TR) after NCT.
METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2− invasive breast cancer (IBC)
who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; >50%), pathologic
complete response (pCR) and breast conserving surgery (BCS) rates were measured.
RESULTS: Median RS was 20 (2–69). Median %TR was 42 (0–97)%. PR was observed in 43% of patients. There was no
association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p> 0.05). No statistically significant
association with %TR was seen with RS as a categorical or continuous variable (p= 0.21 and 0.7, respectively). Response to
NCT improved as ER (p= 0.02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p= 0.03).
CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of
the assay prior to NCT requires further study.
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1. Introduction
Breast cancer is the second most common cancer
among women in the US with an estimated 232,340
women being diagnosed with invasive breast cancer in
2013 [23]. Of those, between 30–40% will be diag-
nosed with a locally advanced breast cancer [4,23].
*Corresponding author: Atilla Soran, Magee-Womens Hospital
of UPMC, Suite 2601, 300 Halket Street, Pittsburgh, PA 15213,
USA. Tel.: +1 412 641 4538; Fax: +1 412 641 1446; E-mail:
asoran@upmc.edu.
The most difficult challenge for surgical oncologists
in the treatment of locally advanced breast cancer is
operative planning.
Neoadjuvant chemotherapy (NCT) is standard of
care for patients with locally advanced breast cancer.
Although no study has clearly shown an increase
in disease-free or overall survival compared with
conventional adjuvant chemotherapy for all patients
with breast cancer, in the patient population with
locally advanced disease, this approach has advantages
over adjuvant chemotherapy. An inoperable tumor
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may become operable or become amenable to breast-
conserving surgery; thereby increasing the percentage
of patients who can avoid mastectomy [11,21,27]. It
allows the chance to monitor response to therapy,
which has prognostic implications [25]. It also allows
time for additional testing, such as genetic testing,
which may affect eventual local therapy [15].
Patients with locally advanced triple negative or
HER2 positive tumors are ideal candidates for NCT.
They will generally receive adjuvant chemotherapy, so
its use in the neoadjuvant setting only enhances the
benefit of systemic therapy by expanding options for
locoregional therapy [27]. In contrast, patients with
luminal tumors (estrogen and/or progesterone receptor
positive, HER2 negative) may not require adjuvant
chemotherapy and thus the benefit of preoperative
systemic therapy in this population is limited [10].
Several prognostic markers can be used to guide
the decision to recommend chemotherapy to a patient
with a luminal breast cancer. Both immunohistochem-
istry [26] and several genomic assays can define the
risk of recurrence using endocrine therapy alone, and
some can also predict benefit of adjuvant chemother-
apy [12,18]. The most widely used genomic assay in
the US is the Oncotype DX R© Breast Cancer Assay. It is
designed to quantify the expression of a specific group
of 21 genes (5 genes are reference genes) related to
cell receptors, invasion and proliferation. The Recur-
rence Score, calculated using the Oncotype DX R© test,
has been clinically validated as a predictor of the
likelihood of distant recurrence in patients with node
negative, estrogen receptor positive (ER+) breast can-
cer who were treated with adjuvant tamoxifen [1,17].
The Recurrence Score has also been shown to predict
the likelihood of adjuvant chemotherapy benefit in
the same patient population [18]. Patients with high
results receive the largest benefit from the addition of
chemotherapy while patients with low results receive
little or no benefit from adjuvant chemotherapy.
The ability of such prognostic markers in predict-
ing response to neoadjuvant chemotherapy, however,
remains in question. Literature on the topic varies
according to the assay used. While some support
the use of assays in this capacity [2,7,8,14,16,22,24],
others question their validity in predicting response
to NCT [20]. Few studies concentrate only on ER+
patients and the ability to predict NCT response in this
subset [7,14].
Our study evaluates the ability of the 21-gene assay
(Oncotype DX recurrence score R©) to predict benefit of
NCT in patients with ER+ breast cancer. We hypoth-
esize that a positive association exists between the
Recurrence Score from pre-therapy percutaneous large
core needle biopsy (CNB) and the percentage tumor
response (%TR) after neoadjuvant chemotherapy.
2. Methods
2.1. Patient selection
After receiving IRB approval for the study, clini-
cal and pathologic data was collected retrospectively
for 71 patients with ER+/HER2− invasive ductal
carcinoma of the breast diagnosed with CNB and
treated between 2011 and 2012. All patients were
females, >18 years of age with no prior history of
any cancer, including breast cancer. Patients were diag-
nosed with T1-3 N0-1 M0 tumor in which the tumor
size prevented primary surgical management (either
mastectomy or lumpectomy). Pre-treatment paraffin-
embedded tissue samples were sent to Genomic
Health, Inc. for OncotypeDX R© testing, which was per-
formed following standard procedures while blinded to
clinical and pathology data [17].
2.2. Systemic therapy
Patients received 24 weeks of one of the two
standard neoadjuvant chemotherapy regimens that
consisted of the following agents: doxorubicin,
cyclophosphamide and a taxane. These were admin-
istered per NCCN guidelines [5]. Following comple-
tion of chemotherapy and further imaging, the patient
and her physician decided if mastectomy, breast con-
serving surgery (BCS) or total mastectomy would be
appropriate.
2.3. Measurement of response
Tumor response to chemotherapy was defined as
(1) relative change in tumor size (mm), as measured
by MRI and US, at baseline and after neo-adjuvant
chemotherapy, (2) clinical (partial) response (PR)
defined as at least 50% reduction in area on imag-
ing, (3) pathologic complete response (pCR) defined
as complete absence of viable invasive tumor cells
on pathologic examination, including surgical margins
and lymph nodes. A clinically significant endpoint was
defined as the ability of the patient to undergo BCS.
Percentage tumor size reduction (%TR) was based
on pre-therapy size (largest dimension) and detailed
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pathology evaluation of the resection specimen.
The pre-therapy tumor size was abstracted from
clinical charts. Modality was selected in the fol-
lowing preferential order: MRI, ultrasound, mam-
mogram, physical examination maximum dimension
(uni-dimensional measurement). The post-therapy
tumor size was defined as the product of: maximum
dimension of tumor-bed (or area of fibrosis) × per-
centage cellularity (compared with pre-therapy biopsy)
of the tumor-bed (or area of fibrosis) by microscopic
exam. %TR was calculated as the difference between
the pre and post-therapy tumor size divided by pre-
therapy tumor size, multiplied by 100 (available at
http://path.upmc.edu/onlineTools/ptvr.html).
2.4. Statistical considerations
The clinical and demographics characteristics of
the study sample were summarized using descriptive
statistics. The association between Recurrence Score
and both clinical and pathologic response to neoad-
juvant chemotherapy were assessed. Differences in
continuous variables were analyzed using the Mann–
Whitney U test. Categorical variables were analyzed
using Chi-square tests. Linear regression models were
used to examine if the changes in largest tumor
dimension (mm) and/or %TR were associated with
the Recurrence Score at baseline (i.e. core biopsy).
Additionally other explorative analyses were con-
ducted using the tumor volume (mm3), instead of uni-
dimensional tumor size (in mm), and using the ratio of
the difference in pre- and post-treatment tumor mea-
surements. Logistic regression was used to examine,
by odds ratio (OR), the association between the Recur-
rence Score and the binary (i.e. presence, absence)
response variables: clinical response and pathologic
response. We examined the effect of Recurrence Score
modeling it both as a continuous variable result as
well as the 3 categories (low, intermediate and high
risk). All hypotheses were tested with an α of 0.05.
All statistical tests were performed using SAS/STAT R©
version 9.3 (Copyright c© 2002–2010. SAS Institute,
Inc., Cary, NC).
3. Results
Out of the total of 71 core biopsy samples submitted
to Genomic Health for testing, two samples failed
RNA extraction and the remaining 69 patient samples
were processed by RT-PCR. There were no RT-PCR
failures. 9 samples were identified as HER2+ by RT-
PCR, and excluded from analysis of Recurrence Score
Table 1
Clinicopathologic characteristics
n= 60
Age 52 (range 28–86)
Tumor size 48 mm (range 10–230)
Receptor status by IHC
ER positive 60 (100%)
PR positive 52 (87%)
HER2 positive 0 (0%)
Lymph node status at baseline
Negative 50 (83%)
Positive 10 (17%)
Nuclear grade∗
1 4 (7%)
2 43 (73%)
3 12 (20%)
∗1 patient with missing Nottingham score and grade.
Table 2
Recurrence Score (RS) distribution
Recurrence Score group n (%)
Low risk (<18) 27 (45%)
Intermediate risk (18–30) 10 (17%)
High risk (>31) 23 (38%)
versus tumor response, leaving 60 patients evaluable
for that analysis. Patients who were HER2+ by RT-
PCR remained in the study for purpose of comparison
of clinicopathologic factors with tumor response.
3.1. Patient/tumor characteristics
The mean patient age was 52 years (range 28–86).
The mean tumor size (mm) was 48 (range 10–230). Of
the 60 evaluable samples, 60 (100%) were ER positive
and 52 (87%) were PR positive. 50 (83%) patients
had no lymph node involvement, while 10 (17%) were
clinically and/or pathologically N1 at presentation.
The most common nuclear grade was 2 (73%) on the
core biopsy (Table 1).
The 21-gene assay calculated by Genomic Health
for each of the 60 evaluable specimens, demonstrated
a low (<18) in 27 (45%), intermediate (18–30) in 10
(17%) and high (>31) Recurrence Score in 23 (38%)
specimens (Table 2).
3.2. Response/outcome
All 60 patients completed 24 weeks of neoadjuvant
chemotherapy, but none had a pCR. The median %TR
was 42% (range 0–97%). A partial clinical response
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(A) (B)
(C)
Fig. 1. Recurrence Score versus clinicopathologic features at presentation. (A) (Baseline tumor size) Spearman correlation = 0.05 (95%
CI =−0.21, 0.30; p= 0.61); regression r2 = 0.04, p= 0.62. (B) (Age) Spearman correlation = −0.10 (95% CI =−0.35, 0.16; p= 0.50);
regression r2 = 0.08, p= 0.50. (C) (Nuclear grade) Spearman correlation= 0.51 (95% CI = 0.29, 0.68; P< 0.001). (Colours are visible in the
online version of the article; http://dx.doi.org/10.3233/BD-150199)
(>50% reduction in largest tumor dimension) was
observed in 26 (43%) patients. No patients had disease
progression. 17 (28%) patients underwent BCS and 43
(72%) underwent mastectomy.
3.3. Recurrence score and baseline characteristics
Recurrence Score was not significantly correlated
with tumor size at presentation or patient age but it was
correlated with nuclear grade on core biopsy (Fig. 1).
3.4. Recurrence score and outcome
Recurrence Score also did not correlate with %TR
(p= 0.07) when adjusting for pre-treatment size, or
when the covariate adjustment was removed from the
model (p= 0.06) (Fig. 2).
Neither nodal status (p= 0.79), patient age
(p=0.99), baseline tumor size (p=0.38), nor nuclear
grade (p= 0.18) were associated with continuous
%TR. The mean %TR in the high risk Recurrence
Score group was not significantly greater than in the
intermediate risk group (Table 3).
Lower values of ER by RT-PCR were associated
with increased reduction in tumor size (p= 0.02). PR
by RT-PCR was not associated with reduction in tumor
size (p= 0.32). Lower ER expression by IHC corre-
lated with improved response (p= 0.03). However, PR
and HER2 by IHC did not correlate with response
(p= 0.09 and p= 0.37, respectively). Interestingly,
lower values of HER2 by RT-PCR were also associated
with increased reduction in tumor size (p= 0.007).
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Table 3
Percent tumor volume reduction and clinical response in tumor size by RS Group
RS group % Tumor volume reduction∗ Clinical response∗∗
Mean ± SD Response/total (%)
Low risk (<18) 35.1± 26 10/27= 37%
Intermediate risk (18–30) 54.4± 32 6/10= 60%
High risk (>31) 45.6± 37 11/23= 48%
∗p= 0.21 and ∗∗p= 0.43 for comparison among 3 RS groups.
Fig. 2. Percent tumor response versus recurrence score. Regression
r2 = 0.06, p= 0.06.
There was no significant association between partial
clinical response and patient age (p= 0.54), baseline
tumor size (p= 0.78), nuclear grade (p= 0.96), or
nodal status (p= 0.82). The continuous Recurrence
Score was not significantly associated with the odds
of response (p= 0.15). There was no trend in response
by low, intermediate or high risk category (p= 0.43).
Due to a lack of association between both the contin-
uous or categorical Recurrence Score and response,
no attempt was made to identify an optimal score
threshold for predicting response. There was a sta-
tistically non-significant inverse relationship between
continuous ER by RT-PCR and the odds of response
(p= 0.08, OR = 0.72 per CT, 95% CI = 0.49, 1.05).
There was no significant difference in the rate of BCS
between responders (7/26 = 27%) and non-responders
(10/34 = 29%) (p= 0.83).
4. Discussion
The Oncotype DX R© 21-gene assay is well described
as an accurate method of assessing risk of recurrence
in patients with ER+ invasive breast cancer [9,17].
In addition, it is a prediction tool in determining the
benefit of chemotherapy in the adjuvant setting for
both node negative and node positive patients [1,18].
However, the ability of this assay to predict the benefit
of chemotherapy in the neoadjuvant setting remains
controversial [7,14].
In our study, we found no statistically significant
association between the Recurrence Score and %TR
with NCT. These results reflect the findings of Mina et
al. who found that the Recurrence Score did not predict
pCR in patients undergoing NCT [14]. In contrast,
Gianni et al. determined that Recurrence Score did,
in fact, predict for pCR [7]. A finding common to
many studies is the ability of lower ER expression
by RT-PCR to predict tumor volume reduction and/or
pCR [7,8,16].
It is important to note that no statistically significant
associations were demonstrated between baseline clin-
ical and pathology factors and %TR with NCT. How-
ever, the non-significant increase (p= 0.07) in %TR as
Recurrence Score increases suggests that with a larger
cohort, Recurrence Score may be more predictive than
standard patient and tumor characteristics at predicting
benefit of NCT. This study and others suggest that
ER expression is superior to standard clinicopathologic
factors at predicting response.
Regardless of the ability of RS to predict response
to neoadjuvant chemotherapy, it is well established
that the 21-gene assay provides important predic-
tive and prognostic information and affects the deci-
sion on chemotherapy given [1,18]. If an Oncotype
DX R© recurrence score predicts recurrence free sur-
vival in the adjuvant setting, giving chemotherapy
in the neoadjuvant setting should not change that
benefit [19]. Thus it can be used as an important
decision tool when trying to decide between primary
surgery, neoadjuvant chemotherapy or even neoadju-
vant endocrine therapy.
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In our study, 55% of patients had an intermediate
or high RS. This population would most likely receive
adjuvant CT, and in this group of patients the mean
%TR was 54.4% and 45.6%, respectively. Therefore,
one may suggest that RS from a core biopsy not only
predicts for overall CT benefit and prognostic informa-
tion for recurrence (regardless of order in which it is
given) but may also provide an indication of patients
who are most likely to see a 50% tumor reduction.
On the other hand, patients with a low RS on their
original core biopsy may derive little survival or tumor
downstaging benefit from NCT. In our study 45% of
the patients had a low RS, resulting in an average 35%
TR. In this group of patients, awaiting a RS on the
final surgical specimen, along with other pathologic
data, may guide adjuvant therapy decisions better.
Alternately, one might consider neoadjuvant endocrine
therapy for this population [6].
There are several limitations to our study. Fewer
than half of the planned 130 evaluable patients were
available for analysis (due to low use of NCT for
patients with ER+, HER2− tumors institutionally);
which may have affected our ability to prove statistical
significance. This is a small, single institution study,
and there were two different NCT regimens admin-
istered. Interestingly, no pCRs were observed among
the 60 patients evaluable for this analysis, making
this endpoint impossible to study. Our institutional
average pCR in the ER/PR+ population is 7%, reflect-
ing national data [13]. There were also no instances
of disease progression during NCT. Finally, special
methods developed by Magee-Womens Hospital of
UPMC for measuring reduction in tumor size were
employed [3]. It is possible that other methods (e.g.,
RECIST criteria) of tumor measurement and response
may yield different results.
In our cohort of patients with ER+ invasive breast
cancer, where NCT was recommended for tumor
downstaging, Recurrence Score did not successfully
identify patients who would respond to NCT as mea-
sured by %TR. While there was a trend toward better
response with higher scores, the result was nonsignif-
icant, but this may be a function of our underpowered
sample size. Lower ER expression, as measured by RT-
PCR and IHC, was predictive of an improved response
to NCT, which confirms the findings of other investi-
gators. Further study into using this genomic assay to
predict long-term recurrence free survival benefit from
preoperative neoadjuvant chemotherapy or endocrine
therapy may better delineate the benefit of the assay’s
use in the preoperative setting.
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